跳转至内容
Merck
CN

PHI90001

D-丝氨酸(第8位)修饰多肽结构变体

GLP-1 Agonist Impurity, analytical standard, Numbering in the name as per API

别名:

D-Ser(14)-Liraglutide [GLP-1 numbering], H-His-Ala-Glu-Gly-Thr-Phe-Thr-D-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

登录并加购,请在购物车里查看协议价、货期和发货地。

选择规格

变更视图

关于此项目

经验公式(希尔记法):
C172H265N43O51
分子量:
3751.20
UNSPSC Code:
41116107
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

analytical standard

Quality Segment

API family

liraglutide, liraglutide, liraglutide, liraglutide

form

powder, solid

technique(s)

HPLC: suitable, LC/MS: suitable, liquid chromatography (LC): suitable, mass spectrometry (MS): suitable

color

white to off-white

format

neat

storage temp.

−20°C

SMILES string

OC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](N)CC1=CNC=N1)=O)C)=O)CCC(O)=O)=O)=O)[C@@H](C)O)=O)CC2=CC=CC=C2)=O)[C@@H](C)O)=O)CO)=O)CC(O)=O)=O)C(C)C)=O)CO)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@@H](CC3=CC=CC=C3)C(N[C@H](C(N[C@@H](C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CCCNC(N)=N)C(NCC(O)=O)=O)=O)=O)=O)C(C)C)=O)CC(C)C)=O)CC4=CNC5=CC=CC=C45)=O)=O)[C@H](CC)C)=O)=O)=O)CCCCNC(CC[C@H](NC(CCCCCCCCCCCCCCC)=O)C(O)=O)=O)=O)C)=O)C)=O)CCC(N)=O)=O)=O)CCC(O)=O)=O)CC(C)C)=O)CC6=CC=C(C=C6)O)=O

General description

The analytical standard of D-Ser(8)-Liraglutide is a stereoisomeric impurity of Liraglutide in which the L-Serine residue at position 8, API numbering (and position 14 in GLP-1 numbering) is replaced by its D-enantiomer (D-Ser). This single chiral inversion, two residues from the N-terminus, can arise during solid-phase peptide synthesis (SPPS) through incomplete chiral control or racemisation under acidic/basic coupling conditions. The compound retains the full 31-residue backbone of Liraglutide and carries the characteristic palmitoyl–γGlu–Lys26 fatty acid conjugate responsible for albumin binding and extended half-life. However, the D-amino acid substitution is expected to locally distort the α-helical secondary structure, potentially altering GLP-1 receptor binding affinity and metabolic stability.

Application

Used as an analytical standard for the identification and semi-quantification of the D-Ser-8 stereoisomeric impurity in Liraglutide API by reversed-phase HPLC, chiral chromatography, and LC-MS/MS methods.


象形图

Health hazard

警示词

Warning

危险代码

Hazard Classifications

Repr. 2

存储类别

11 - Combustible Solids

闪点 (F)

Not applicable

闪点 (°C)

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库